| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10968296 | Vaccine | 2011 | 11 Pages |
Abstract
⺠Phase I clinical trial evaluating the tolerability and immunogenicity of a Matrix M⢠adjuvanted virosomal H5N1 vaccine. ⺠Vaccination elicited homologous and heterologous H5N1-specific antibody responses. ⺠Two doses of Matrix M⢠adjuvanted 1.5 μg HA virosomal met all the EU regulatory criteria. ⺠Matrix M⢠adjuvant was well tolerated and augmented the antibody response allowing considerable dose sparing down to 1.5 μg HA. ⺠Comparison of the antibody responses by haemagglutination inhibition (HI), microneutralisation (MN) and single radial haemolysis (SRH) serological assays.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Rebecca J. Cox, Gabriel Pedersen, Abdullah S. Madhun, Signe Svindland, Marianne Sævik, Lucy Breakwell, Katja Hoschler, Marieke Willemsen, Laura Campitelli, Jane Kristin Nøstbakken, Gerrit Jan Weverling, Jaco Klap, Kenneth C. McCullough, Maria Zambon,